

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of)

Robert L. Lundak)

Serial No. 247,656)

Filed: March 26, 1981)

For: HIGH FUSION FREQUENCY)
FUSIBLE LYMPHOBLASTOID)
CELL LINE)

Examiner: J. Tarcza

Art Unit: 172

DECLARATION

San Francisco, CA 94105

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

I, Robert L. Lundak, hereby declare as follows:

I am the sole inventor of the above-referenced application and developed the WI-L2-729-HF₂ hybridoma cell line which is described and claimed in said application.

On March 26, 1981, the filing date of the subject application, and at all times thereafter, the WI-L2-729-HF₂ hybridoma cell line was stored at the University of California, Riverside, at three separate locations, including my own laboratory, the laboratory of Dr. Bruce Devens, and the laboratory of Dr. Richard Lubin. Multiple ampules of the cell line were stored in liquid nitrogen at each location. The purpose of the separate storage at different locations was to assure the permanent maintenance of the cell line and to protect against accidental loss.

The cell line was also stored at the laboratory of Dr. John Lewis at the Loma Linda University Medical Center, Loma Linda, California. The cell line was released to Dr. Lewis in order to allow him to characterize the cell line. Dr. Lewis has since maintained the cell line as further protection against its loss.

182
R.M. Z.
4/14/83
9/Dec/83
Apr 12 2 13 PM '83
GROUP 170
RECEIVED
W/da

At all times since March 26, 1981, the filing date herein, the subject WI-L2-729-HF₂ cell line has been maintained by me, /and by others on my behalf, /with all necessary precautions taken to assure its permanence and availability.

The undersigned declarant declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

3/23/83

By:

Robert L. Lundak

Robert L. Lundak